We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

22 hedge funds and large institutions have $5.23M invested in Soleno Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $37K | Put options by funds: $24K

35.93% more ownership

Funds ownership: 2.71% → 38.64% (+36%)

41% less capital invested

Capital invested by funds: $8.8M → $5.23M (-$3.57M)

45% less funds holding

Funds holding: 40 → 22 (-18)

77% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 13

86% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 21

Holders
22
Holders Change
-18
Holders Change %
-45%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
13
Closed
21
Calls
$37K
Puts
$24K
Net Calls
+$13K
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
CP
Clayton Partners
California
+$243K
2
JGC
J. Goldman & Co
New York
+$110K
3
Renaissance Technologies
Renaissance Technologies
New York
+$20.2K
4
Morgan Stanley
Morgan Stanley
New York
+$1.58K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.51K

Top Sellers

Rank Fund Capital Flow
1
OIM
Oracle Investment Management
Connecticut
-$394K
2
NCM
Nantahala Capital Management
Connecticut
-$60.7K
3
Citadel Advisors
Citadel Advisors
Florida
-$55K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$43K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$35.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$2.01M -$2 -1 -0%
NCM
2
Nantahala Capital Management
Connecticut
$1.01M -$60.7K -24,922 -4%
ACM
3
AIGH Capital Management
Maryland
$708K -$2 -1 -0%
BC
4
Birchview Capital
Vermont
$409K – – –
GPCM
5
Granite Point Capital Management
Massachusetts
$295K -$2 -1 -0%
Vanguard Group
6
Vanguard Group
Pennsylvania
$202K -$35.6K -14,634 -11%
WVP
7
Worth Venture Partners
New Jersey
$176K -$2 -1 -0%
CP
8
Clayton Partners
California
$167K +$243K +100,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$75K +$20.2K +8,279 +23%
JGC
10
J. Goldman & Co
New York
$75K +$110K +44,999 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$54K -$10 -4 -0%
State Street
12
State Street
Massachusetts
$26K -$2 -1 -0%
BNP Paribas Financial Markets
13
BNP Paribas Financial Markets
France
$15.6K -$5 -2 -0%
BG
14
Bollard Group
Massachusetts
$4K – – –
Group One Trading
15
Group One Trading
Illinois
$1K -$2 -1 -0.3%
TRCT
16
Tower Research Capital (TRC)
New York
$1K +$1.51K +620 +256%
Morgan Stanley
17
Morgan Stanley
New York
$1K +$1.58K +649 New
OIM
18
Oracle Investment Management
Connecticut
– -$394K -142,133 Closed
Citadel Advisors
19
Citadel Advisors
Florida
– -$55K -19,687 Closed
Two Sigma Advisers
20
Two Sigma Advisers
New York
– -$43K -15,467 Closed
Two Sigma Investments
21
Two Sigma Investments
New York
– -$28K -9,970 Closed
Northern Trust
22
Northern Trust
Illinois
– -$20K -7,032 Closed
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
– -$18K -6,667 Closed
OC
24
Oppenheimer & Co
New York
– -$18K -6,537 Closed
WAM
25
Warberg Asset Management
Illinois
– -$16K -6,000 Closed
1
2

SLNO Hedge Fund Activity: Q3 2022 in Review

22 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2022, worth a combined $5.23M — down 41% from $8.8M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of SLNO and 3 opened new positions — a net loss of 18 holders — while 13 trimmed existing stakes and 3 added.

The largest buyer was Clayton Partners, opening a new position worth an estimated $243K. The largest seller was Oracle Investment Management, exiting entirely with an estimated $394K sold.

  • 22 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2022, down from 40 in Q2 2022.
  • Funds reported $5.23M of Soleno Therapeutics stock for Q3 2022, down 41% quarter-over-quarter.
  • 3 funds opened new Soleno Therapeutics positions in Q3 2022 and 21 closed out, a net change of -18 holders.
  • The largest Soleno Therapeutics buyer in Q3 2022 was Clayton Partners, an estimated $243K added.
  • The largest Soleno Therapeutics seller in Q3 2022 was Oracle Investment Management, an estimated $394K sold.

Based on aggregated 13F filings for Q3 2022.